BACKGROUND: Although comorbidity has been shown to affect the benefits and risks of colorectal cancer (CRC) screening, it has not been accounted for in prior cost-effectiveness analyses of CRC screening. OBJECTIVE: To evaluate the impact of diagnosis of diabetes mellitus, a highly prevalent comorbidity in U.S. adults aged 50 and older, on health and economic outcomes of CRC screening. DESIGN: Cost-effectiveness analysis using an integrated modeling framework. DATA SOURCES: Derived from basic and epidemiologic studies, clinical trials, cancer registries, and a colonoscopy database. TARGET POPULATION: U.S. 50-year-old population. TIME HORIZON: Lifetime. PERSPECTIVE: Costs are based on Medicare reimbursement rates. INTERVENTIONS: Colonoscopy screening at ten-year intervals, beginning at age 50, and discontinued after age 50, 60, 70, 80 or death. OUTCOME MEASURES: Health outcomes and cost effectiveness. RESULTS OF BASE-CASE ANALYSIS: Diabetes diagnosis significantly affects cost-effectiveness of CRC screening. For the same CRC screening strategy, a person without diabetes at age 50 gained on average 0.07-0.13 life years more than a person diagnosed with diabetes at age 50 or younger. For a population of 1,000 patients diagnosed with diabetes at baseline, increasing stop age from 70 years to 80 years increased quality-adjusted life years (QALYs) gained by 0.3, with an incremental cost-effectiveness ratio of $206,671/QALY. The corresponding figures for 1,000 patients without diabetes are 2.3 QALYs and $46,957/QALY. RESULTS OF SENSITIVITY ANALYSIS: Cost-effectiveness results are sensitive to cost of colonoscopy and adherence to colonoscopy screening. LIMITATIONS: Results depend on accuracy of model assumptions. CONCLUSION: Benefits of CRC screening differ substantially for patients with and without diabetes. Screening for CRC in patients diagnosed with diabetes at age 50 or younger is not cost-effective beyond age 70. Screening recommendations should be individualized based on the presence of comorbidities.
BACKGROUND: Although comorbidity has been shown to affect the benefits and risks of colorectal cancer (CRC) screening, it has not been accounted for in prior cost-effectiveness analyses of CRC screening. OBJECTIVE: To evaluate the impact of diagnosis of diabetes mellitus, a highly prevalent comorbidity in U.S. adults aged 50 and older, on health and economic outcomes of CRC screening. DESIGN: Cost-effectiveness analysis using an integrated modeling framework. DATA SOURCES: Derived from basic and epidemiologic studies, clinical trials, cancer registries, and a colonoscopy database. TARGET POPULATION: U.S. 50-year-old population. TIME HORIZON: Lifetime. PERSPECTIVE: Costs are based on Medicare reimbursement rates. INTERVENTIONS: Colonoscopy screening at ten-year intervals, beginning at age 50, and discontinued after age 50, 60, 70, 80 or death. OUTCOME MEASURES: Health outcomes and cost effectiveness. RESULTS OF BASE-CASE ANALYSIS: Diabetes diagnosis significantly affects cost-effectiveness of CRC screening. For the same CRC screening strategy, a person without diabetes at age 50 gained on average 0.07-0.13 life years more than a person diagnosed with diabetes at age 50 or younger. For a population of 1,000 patients diagnosed with diabetes at baseline, increasing stop age from 70 years to 80 years increased quality-adjusted life years (QALYs) gained by 0.3, with an incremental cost-effectiveness ratio of $206,671/QALY. The corresponding figures for 1,000 patients without diabetes are 2.3 QALYs and $46,957/QALY. RESULTS OF SENSITIVITY ANALYSIS: Cost-effectiveness results are sensitive to cost of colonoscopy and adherence to colonoscopy screening. LIMITATIONS: Results depend on accuracy of model assumptions. CONCLUSION: Benefits of CRC screening differ substantially for patients with and without diabetes. Screening for CRC in patients diagnosed with diabetes at age 50 or younger is not cost-effective beyond age 70. Screening recommendations should be individualized based on the presence of comorbidities.
Authors: Shirley A A Beresford; Karen C Johnson; Cheryl Ritenbaugh; Norman L Lasser; Linda G Snetselaar; Henry R Black; Garnet L Anderson; Annlouise R Assaf; Tamsen Bassford; Deborah Bowen; Robert L Brunner; Robert G Brzyski; Bette Caan; Rowan T Chlebowski; Margery Gass; Rosanne C Harrigan; Jennifer Hays; David Heber; Gerardo Heiss; Susan L Hendrix; Barbara V Howard; Judith Hsia; F Allan Hubbell; Rebecca D Jackson; Jane Morley Kotchen; Lewis H Kuller; Andrea Z LaCroix; Dorothy S Lane; Robert D Langer; Cora E Lewis; JoAnn E Manson; Karen L Margolis; Yasmin Mossavar-Rahmani; Judith K Ockene; Linda M Parker; Michael G Perri; Lawrence Phillips; Ross L Prentice; John Robbins; Jacques E Rossouw; Gloria E Sarto; Marcia L Stefanick; Linda Van Horn; Mara Z Vitolins; Jean Wactawski-Wende; Robert B Wallace; Evelyn Whitlock Journal: JAMA Date: 2006-02-08 Impact factor: 56.272
Authors: Iris Lansdorp-Vogelaar; Roman Gulati; Angela B Mariotto; Clyde B Schechter; Tiago M de Carvalho; Amy B Knudsen; Nicolien T van Ravesteyn; Eveline A M Heijnsdijk; Chester Pabiniak; Marjolein van Ballegooijen; Carolyn M Rutter; Karen M Kuntz; Eric J Feuer; Ruth Etzioni; Harry J de Koning; Ann G Zauber; Jeanne S Mandelblatt Journal: Ann Intern Med Date: 2014-07-15 Impact factor: 25.391
Authors: Hisani N Horne; Darcy F Phelan-Emrick; Craig E Pollack; Diane Markakis; Jennifer Wenzel; Saifuddin Ahmed; Mary A Garza; Gary R Shapiro; Lee R Bone; Lawrence B Johnson; Jean G Ford Journal: Cancer Causes Control Date: 2014-12-17 Impact factor: 2.506
Authors: Carrie N Klabunde; Yingye Zheng; Virginia P Quinn; Elisabeth F Beaber; Carolyn M Rutter; Ethan A Halm; Jessica Chubak; Chyke A Doubeni; Jennifer S Haas; Aruna Kamineni; Marilyn M Schapira; Pamela M Vacek; Michael P Garcia; Douglas A Corley Journal: Am J Prev Med Date: 2016-06-22 Impact factor: 5.043
Authors: Linnaea Schuttner; Stacey Hockett Sherlock; Carol Simons; James D Ralston; Ann-Marie Rosland; Karin Nelson; Jennifer R Lee; George Sayre Journal: BMC Prim Care Date: 2022-02-05
Authors: Mikey B Lebrett; Haval Balata; Matthew Evison; Denis Colligan; Rebecca Duerden; Peter Elton; Melanie Greaves; John Howells; Klaus Irion; Devinda Karunaratne; Judith Lyons; Stuart Mellor; Amanda Myerscough; Tom Newton; Anna Sharman; Elaine Smith; Ben Taylor; Sarah Taylor; Anna Walsham; James Whittaker; Phil V Barber; Janet Tonge; Hilary A Robbins; Richard Booton; Philip A J Crosbie Journal: Thorax Date: 2020-07-06 Impact factor: 9.102